Biotech industry and investment community should get "used to" not-approvable letters, two execs say.
BIOTECHNOLOGY INDUSTRY SHOULD GET "USED TO" NON-APPROVABLE LETTERS, Athena Neurosciences CEO John Groom told investors at the Twentieth Annual Alex. Brown Healthcare Seminar May 18 in Baltimore. "I think we as an industry have to probably get more used to non-approvable type letters," Groom suggested. Such a letter "doesn't mean to say the drug won't be approved," Groom told the investment meeting. "It means to say that you have issues that you have to deal with the FDA."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth